484 related articles for article (PubMed ID: 29474847)
1. Serum miRNA Predicts Viable Disease after Chemotherapy in Patients with Testicular Nonseminoma Germ Cell Tumor.
Leão R; van Agthoven T; Figueiredo A; Jewett MAS; Fadaak K; Sweet J; Ahmad AE; Anson-Cartwright L; Chung P; Hansen A; Warde P; Castelo-Branco P; O'Malley M; Bedard PL; Looijenga LHJ; Hamilton RJ
J Urol; 2018 Jul; 200(1):126-135. PubMed ID: 29474847
[TBL] [Abstract][Full Text] [Related]
2. Real-World Application of Pre-Orchiectomy miR-371a-3p Test in Testicular Germ Cell Tumor Management.
Badia RR; Abe D; Wong D; Singla N; Savelyeva A; Chertack N; Woldu SL; Lotan Y; Mauck R; Ouyang D; Meng X; Lewis CM; Majmudar K; Jia L; Kapur P; Xu L; Frazier AL; Margulis V; Strand DW; Coleman N; Murray MJ; Amatruda JF; Lafin JT; Bagrodia A
J Urol; 2021 Jan; 205(1):137-144. PubMed ID: 32856980
[TBL] [Abstract][Full Text] [Related]
3. Circulating serum miRNA (miR-367-3p, miR-371a-3p, miR-372-3p and miR-373-3p) as biomarkers in patients with testicular germ cell cancer.
Syring I; Bartels J; Holdenrieder S; Kristiansen G; Müller SC; Ellinger J
J Urol; 2015 Jan; 193(1):331-7. PubMed ID: 25046619
[TBL] [Abstract][Full Text] [Related]
4. Clinical utility of plasma miR-371a-3p in germ cell tumors.
Mego M; van Agthoven T; Gronesova P; Chovanec M; Miskovska V; Mardiak J; Looijenga LHJ
J Cell Mol Med; 2019 Feb; 23(2):1128-1136. PubMed ID: 30536846
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of miR-371a-3p to predict viable germ cell tumor in patients with pure seminoma receiving retroperitoneal lymph node dissection.
Konneh B; Lafin JT; Howard J; Gerald T; Amini A; Savelyeva A; Woldu SL; Lewis CM; Jia L; Margulis V; Coleman N; Scarpini C; Frazier AL; Murray MJ; Amatruda JF; Bagrodia A
Andrology; 2023 May; 11(4):634-640. PubMed ID: 36254623
[TBL] [Abstract][Full Text] [Related]
6. MicroRNA miR-371a-3p in serum of patients with germ cell tumours: evaluations for establishing a serum biomarker.
Spiekermann M; Belge G; Winter N; Ikogho R; Balks T; Bullerdiek J; Dieckmann KP
Andrology; 2015 Jan; 3(1):78-84. PubMed ID: 25187505
[TBL] [Abstract][Full Text] [Related]
7. Serum Levels of MicroRNA miR-371a-3p: A Sensitive and Specific New Biomarker for Germ Cell Tumours.
Dieckmann KP; Radtke A; Spiekermann M; Balks T; Matthies C; Becker P; Ruf C; Oing C; Oechsle K; Bokemeyer C; Hammel J; Melchior S; Wosniok W; Belge G
Eur Urol; 2017 Feb; 71(2):213-220. PubMed ID: 27495845
[TBL] [Abstract][Full Text] [Related]
8. Serum Levels of MicroRNA-371a-3p (M371 Test) as a New Biomarker of Testicular Germ Cell Tumors: Results of a Prospective Multicentric Study.
Dieckmann KP; Radtke A; Geczi L; Matthies C; Anheuser P; Eckardt U; Sommer J; Zengerling F; Trenti E; Pichler R; Belz H; Zastrow S; Winter A; Melchior S; Hammel J; Kranz J; Bolten M; Krege S; Haben B; Loidl W; Ruf CG; Heinzelbecker J; Heidenreich A; Cremers JF; Oing C; Hermanns T; Fankhauser CD; Gillessen S; Reichegger H; Cathomas R; Pichler M; Hentrich M; Eredics K; Lorch A; Wülfing C; Peine S; Wosniok W; Bokemeyer C; Belge G
J Clin Oncol; 2019 Jun; 37(16):1412-1423. PubMed ID: 30875280
[TBL] [Abstract][Full Text] [Related]
9. A New Model to Predict Benign Histology in Residual Retroperitoneal Masses After Chemotherapy in Nonseminoma.
Leão R; Nayan M; Punjani N; Jewett MAS; Fadaak K; Garisto J; Lewin J; Atenafu EG; Sweet J; Anson-Cartwright L; Boström P; Chung P; Warde P; Bedard PL; Bagrodia A; Freifeld Y; Power N; Winquist E; Hamilton RJ
Eur Urol Focus; 2018 Dec; 4(6):995-1001. PubMed ID: 29428550
[TBL] [Abstract][Full Text] [Related]
10. microRNA-371a-3p as informative biomarker for the follow-up of testicular germ cell cancer patients.
van Agthoven T; Eijkenboom WMH; Looijenga LHJ
Cell Oncol (Dordr); 2017 Aug; 40(4):379-388. PubMed ID: 28612337
[TBL] [Abstract][Full Text] [Related]
11. Post-chemotherapy retroperitoneal teratoma in nonseminomatous germ cell tumors: Do predictive factors exist? Results from a national multicenter study.
Dusaud M; Malavaud B; Bayoud Y; Sebe P; Hoepffner JL; Salomon L; Houlgatte A; Pignot G; Rigaud J; Fléchon A; Pfister C; Rouprêt M; Soulié M; Méjean A; Durand X
J Surg Oncol; 2016 Dec; 114(8):992-996. PubMed ID: 27859263
[TBL] [Abstract][Full Text] [Related]
12. Serum MicroRNA-371a-3p Levels Predict Viable Germ Cell Tumor in Chemotherapy-naïve Patients Undergoing Retroperitoneal Lymph Node Dissection.
Lafin JT; Singla N; Woldu SL; Lotan Y; Lewis CM; Majmudar K; Savelyeva A; Kapur P; Margulis V; Strand DW; Murray MJ; Amatruda JF; Bagrodia A
Eur Urol; 2020 Feb; 77(2):290-292. PubMed ID: 31699528
[No Abstract] [Full Text] [Related]
13. miR-371a-3p, miR-373-3p and miR-367-3p as Serum Biomarkers in Metastatic Testicular Germ Cell Cancers Before, During and After Chemotherapy.
Rosas Plaza X; van Agthoven T; Meijer C; van Vugt MATM; de Jong S; Gietema JA; Looijenga LHJ
Cells; 2019 Oct; 8(10):. PubMed ID: 31597402
[TBL] [Abstract][Full Text] [Related]
14. Clinical outcome following post-chemotherapy retroperitoneal lymph node dissection in men with intermediate- and poor-risk nonseminomatous germ cell tumour.
Shayegan B; Carver BS; Stasi J; Motzer RJ; Bosl GJ; Sheinfeld J
BJU Int; 2007 May; 99(5):993-7. PubMed ID: 17437432
[TBL] [Abstract][Full Text] [Related]
15. High Expression of microRNA-371a-3p in Cystic Fluid of Post-Chemotherapy Teratoma with Concurrent Normal Serum Levels in Patients with Non-Seminomatous Testicular Germ Cell Tumours.
Dieckmann KP; Hennig F; Anheuser P; Gehrckens R; Viehweger F; Wülfing C; Belge G
Urol Int; 2021; 105(1-2):21-26. PubMed ID: 33049748
[TBL] [Abstract][Full Text] [Related]
16. Can germ cell neoplasia in situ be diagnosed by measuring serum levels of microRNA371a-3p?
Radtke A; Cremers JF; Kliesch S; Riek S; Junker K; Mohamed SA; Anheuser P; Belge G; Dieckmann KP
J Cancer Res Clin Oncol; 2017 Nov; 143(11):2383-2392. PubMed ID: 28819887
[TBL] [Abstract][Full Text] [Related]
17. MiR-371a-3p Serum Levels Are Increased in Recurrence of Testicular Germ Cell Tumor Patients.
Terbuch A; Adiprasito JB; Stiegelbauer V; Seles M; Klec C; Pichler GP; Resel M; Posch F; Lembeck AL; Stöger H; Szkandera J; Pummer K; Bauernhofer T; Hutterer GC; Gerger A; Stotz M; Pichler M
Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30321995
[TBL] [Abstract][Full Text] [Related]
18. Clinical Outcome of Patients with Fibrosis/Necrosis at Post-Chemotherapy Retroperitoneal Lymph Node Dissection for Advanced Germ Cell Tumors.
Mano R; Becerra MF; Carver BS; Bosl GJ; Motzer RJ; Bajorin DF; Feldman DR; Sheinfeld J
J Urol; 2017 Feb; 197(2):391-397. PubMed ID: 27720783
[TBL] [Abstract][Full Text] [Related]
19. The combination of microRNA-371a-3p and 375-5p can distinguish viable germ cell tumor and teratoma from necrosis in postchemotherapy retroperitoneal lymph node dissection specimens.
Kremer L; von Brandenstein M; Wittersheim M; Koeditz B; Paffenholz P; Hellmich M; Pfister D; Heidenreich A; Nestler T
Transl Androl Urol; 2021 Apr; 10(4):1647-1655. PubMed ID: 33968653
[TBL] [Abstract][Full Text] [Related]
20. Impact of circulating microRNA test (miRNA-371a-3p) on appropriateness of treatment and cost outcomes in patients with Stage I non-seminomatous germ cell tumours.
Bagrodia A; Savelyeva A; Lafin JT; Speir RW; Chesnut GT; Frazier AL; Woldu SL; Margulis V; Murray MJ; Amatruda JF; Lotan Y
BJU Int; 2021 Jul; 128(1):57-64. PubMed ID: 33124175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]